ADAPTIN BIO, INC.

APTN · OTC · SIC 2836: Biological Products, (No Diagnostic Substances)
19
SEC Filings

Business Summary

PART I . Our Company The Companys objective is to develop and commercialize products utilizing novel technology that enhances the delivery of drugs and other compounds to the brain and other tissues for a variety of indications. Our novel technology was originally developed by researchers in the Department of Neurosurgery at Duke University and licensed by us in 2023. Our website address is www.adaptinbio.com and we can be contacted at info@adaptinbio.com. Information contained on, or that can b...

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAPTNdiscussed_in_filing Cybersecurity
topic_mentionAPTNdiscussed_in_filing Trusted Computing
topic_mentionAPTNdiscussed_in_filing Blockchain & Crypto
topic_mentionAPTNdiscussed_in_filing Regulation
topic_mentionAPTNdiscussed_in_filing Healthcare & Bio
topic_mentionAPTNdiscussed_in_filing Platform & Ecosystem
topic_mentionAPTNdiscussed_in_filing Cybersecurity
topic_mentionAPTNdiscussed_in_filing Trusted Computing
topic_mentionAPTNdiscussed_in_filing Blockchain & Crypto
topic_mentionAPTNdiscussed_in_filing Regulation
topic_mentionAPTNdiscussed_in_filing Healthcare & Bio
topic_mentionAPTNdiscussed_in_filing Platform & Ecosystem
topic_mentionAPTNdiscussed_in_filing Cybersecurity
topic_mentionAPTNdiscussed_in_filing Trusted Computing
topic_mentionAPTNdiscussed_in_filing Blockchain & Crypto
topic_mentionAPTNdiscussed_in_filing Regulation
topic_mentionAPTNdiscussed_in_filing Healthcare & Bio
topic_mentionAPTNdiscussed_in_filing Platform & Ecosystem
topic_mentionAPTNdiscussed_in_filing Cybersecurity
topic_mentionAPTNdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-04-012025-12-310001213900-26-038568EDGAR44K words
2025-04-152024-12-310001213900-25-031878EDGAR—
2024-04-012023-12-310001213900-24-028681EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001213900-25-110559EDGAR21K words
2025-08-142025-06-300001213900-25-076361EDGAR—
2025-05-152025-03-310001213900-25-044083EDGAR—
2024-11-142024-09-300001213900-24-098361EDGAR—
2024-08-142024-06-300001213900-24-068816EDGAR—
2024-05-152024-03-310001213900-24-043492EDGAR—
2023-11-142023-09-300001213900-23-086982EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-060001213900-26-040458EDGAR0K words
2025-12-230001213900-25-125451EDGAR—
2025-10-060001213900-25-096532EDGAR—
2025-04-090001213900-25-030320EDGAR—
2025-02-180001213900-25-014630EDGAR—

19 total filings indexed. 4 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc. ABOS — Acumen Pharmaceuticals, Inc.

Company Identity

CIK0001938571
TickerAPTN
ExchangeOTC
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 9ab8c074836f05264be22b4d9389add20d38b4f1f98dd2fb826ffb0dc01211aa
parent: fda76a0559da494e13904431366931087b1a09bc96eaa35764fe893823400594
content hash: 8b7c82960002a789891e2144d8b378ea239c0da292e67df14f70e9313211126c
signed: 2026-04-13T04:43:41.844Z
sources: 10 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf